Universal Health Receives a Hold from Barclays

By Carrie Williams

Barclays analyst Joshua Raskin reiterated a Hold rating on Universal Health (NYSE: UHS) today and set a price target of $147. The company’s shares closed last Friday at $118.74.

According to TipRanks.com, Raskin is a 4-star analyst with an average return of 4.5% and a 59.7% success rate. Raskin covers the Healthcare sector, focusing on stocks such as WellCare Health Plans, Surgery Partners Inc, and Envision Healthcare.

Currently, the analyst consensus on Universal Health is Hold and the average price target is $136.25, representing a 14.7% upside.

In a report issued on November 9, Mizuho Securities also downgraded the stock to Hold with a $133 price target.

The company has a one year high of $139.77 and a one year low of $100.82. Currently, Universal Health has an average volume of 860.8K.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2015, Debra Osteen, the SVP of UHS sold 11,305 shares for a total of $1,484,111.

Universal Health Services, Inc. operates as a healthcare management company, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. It operates through the Acute Care Hospital Services and Behavioral Health Care Services segments. The company was founded by Alan B. Miller in 1978 and is headquartered in King of Prussia, PA.